UNLIMITED TURBO LONG - INMODE Share Price

Certificat

DE000PC883Q5

Market Closed - Boerse Frankfurt Warrants 20:50:20 20/06/2024 BST
1.72 EUR +18.62% Intraday chart for UNLIMITED TURBO LONG - INMODE
Current month-46.74%
1 month-44.84%
Date Price Change
20/06/24 1.72 +18.62%
19/06/24 1.45 +11.54%
18/06/24 1.3 -41.18%
17/06/24 2.21 +7.28%
14/06/24 2.06 -1.44%

Real-time Boerse Frankfurt Warrants

Last update June 20, 2024 at 08:50 pm

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying INMODE LTD.
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC883Q
ISINDE000PC883Q5
Date issued 03/05/2024
Strike 17.21 $
Maturity Unlimited
Parity 1 : 1
Emission price 0.6
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.33
Lowest since issue 1.3

Company Profile

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Sector
-
More about the company

Ratings for InMode Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: InMode Ltd.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
17.81 USD
Average target price
25.6 USD
Spread / Average Target
+43.74%
Consensus